Patient Transfer to Receive Proton Beam Therapy During Intensive Multimodal Therapy is Safe and Feasible for Patients With Newly Diagnosed High-risk Neuroblastoma.
Patient Transfer to Receive Proton Beam Therapy During Intensive Multimodal Therapy is Safe and Feasible for Patients With Newly Diagnosed High-risk Neuroblastoma.
复制标题
对于新诊断的高危神经母细胞瘤患者来说，在强化多模式治疗期间转移患者接受质子束治疗是安全且可行的。
DOI：
10.1097/mph.0000000000001570
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Takada H
中科院分区：
文献类型：
--
作者：
Hosaka S;Fukushima H;Nakao T;Suzuki R;Yamaki Y;Tanaka K;Saito T;Mizumoto M;Sakurai H;Fukushima T;Takada H
神经母细胞瘤（NB）主要表现为高危疾病，需要强化的多模式治疗。质子束治疗（PBT）是许多儿童癌症的一种有前途的选择，但尚未广泛使用。因此，希望接受PBT的NB患者可能需要在密集的多模式治疗期间在机构之间转移，这有可能产生不良反应。我们评估了在我们研究所接受PBT作为一线治疗的一部分的高危NB患者，主要关注治疗中期患者转移的安全性和可行性。回顾性分析了2010年4月至2016年6月期间接受PBT治疗的18例新诊断的高风险NB患者的局部控制、结局和毒性。生存率（3年总生存率71%±11%; 3年无事件生存率44%±12%）和局部控制率（100%）与既往研究相当。记录的急性不良事件很少，所有患者均完成了PBT，未延迟治疗。高危NB的PBT对于需要治疗中期跨机构转移的患者是安全可行的。
Neuroblastoma (NB) predominantly presents as high-risk disease, requiring intensive multimodal therapy. Proton beam therpy (PBT) is a promising option for many childhood cancers, but is not widely available. Patients with NB hoping to receive PBT may therefore need to be transferred between institutions during intensive multimodal therapy, risking undesirable effects. We evaluated patients with high-risk NB who received PBT at our institute as part of first-line therapy, mainly focusing on the safety and feasibility of mid-treatment patient transfer. Eighteen patients with newly diagnosed high-risk NB who received PBT between April 2010 and June 2016 were retrospectively analyzed for local control, outcomes, and toxicity. Survival (3-y overall survival 71%±11%; 3-y event-free survival 44%±12%) and local control rate (100%) were comparable with previous studies. Few acute adverse events were recorded, and all patients completed PBT without treatment delay. PBT for high-risk NB was safe and feasible for patients requiring mid-treatment interinstitutional transfer.